Abstract
Exosomes, as critical mediators of intercellular communication, transport nucleic acids, proteins, and lipids that drive osteosarcoma (OS) progression and dynamically remodel the tumor microenvironment. Their distinctive biological properties—including low immunogenicity, high stability, and inherent targeting capability—position them as versatile tools across the entire OS management continuum, from early non-invasive diagnosis via liquid biopsy to targeted biotherapy and postoperative bone regeneration through coordinated osteogenesis–angiogenesis coupling. This review first outlines the epidemiological features and principal clinical bottlenecks of OS, then systematically summarizes exosome biogenesis, cellular uptake mechanisms, and the key molecular pathways through which exosomal cargoes regulate OS malignancy. We highlight emerging evidence that exosomal biomarkers enable real-time disease monitoring and that engineered exosomes serve as precision nanocarriers for therapeutic delivery. Notably, we emphasize recent insights into exosome-mediated crosstalk with immune cells within the osteoimmune microenvironment, their role in orchestrating vascularized bone formation, and advances in exosome-functionalized biomaterial scaffolds that effectively bridge tissue engineering with oncology. The clinical relevance of these findings lies in their potential integration into a unified diagnostic–therapeutic–regenerative paradigm, which may help overcome current limitations in surgical outcomes and chemoresistance. Nevertheless, clinical translation remains hindered by persistent challenges, including the lack of standardized isolation and characterization protocols, suboptimal in vivo delivery efficiency, batch-to-batch variability, and insufficient long-term safety data. Addressing these obstacles will require further mechanistic studies and multicenter clinical trials to establish robust regulatory frameworks. This article aims to review the roles of osteosarcoma-derived exosomes in tumor progression, chemoresistance, and bone regeneration, as well as their potential for drug delivery.
Keywords: Osteosarcoma, Exosomes
Introduction
Osteosarcoma (OS) is the most common primary malignant bone tumor, predominantly affecting adolescents during rapid skeletal growth, with a second incidence peak in older adults [1]. It is characterized by high malignancy, strong biological invasiveness, and a marked propensity for early pulmonary metastasis. Currently, the multidisciplinary comprehensive treatment model—centered on neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy—has become the standard clinical regimen for OS [2]. This approach has steadily improved the 5-year overall survival (5y-OSurv) of patients with localized OS to 60%-70%, significantly optimizing survival outcomes [3]. However, overall prognosis has reached a plateau over the past 2 decades, with no substantial breakthrough for patients with de novo metastatic or relapsed/refractory OS [4,5]. This clinical dilemma is largely attributable to the widespread development of chemotherapy resistance and the “cold tumor” characteristics of the OS immune microenvironment, which have become key bottlenecks restricting therapeutic efficacy [6]. On the other hand, although radical extensive tumor resection can further improve survival, it often results in large and complex bone and soft tissue defects, disrupts the local bone microenvironment, and poses difficulties for postoperative functional recovery [7,8]. Effectively filling anatomical defects, eliminating residual lesions, reconstructing normal bone metabolism and mechanical conduction, and achieving orderly bone tissue regeneration have thus become core issues for the success of limb-sparing surgery, directly impacting the long-term quality of life of OS patients.
To address these dual clinical challenges—anti-tumor therapy and postoperative reconstruction—there is an urgent need for novel biological intervention strategies that possess both tumor-suppressive and pro-regenerative capacities. Exosomes are a class of lipid-bilayer extracellular vesicles actively secreted by cells, with diameters ranging from 30 to 150 nm. Widely present in various body fluids, exosomes are characterized by extensive sources and stable structures, serving as natural carriers for intercellular communication [9]. Their core function is to directionally regulate the function and phenotype of recipient cells through the transport of bioactive molecules, including proteins, lipids, and nucleic acids such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), thereby participating in multiple physiological and pathological processes, including tumorigenesis, immune regulation, and tissue regeneration [10]. In oncology, exosomes are deeply involved in OS cell proliferation, invasion, pre-metastatic niche (PMN) formation, metabolic reprogramming, immune escape, and chemoresistance development; their characteristic molecular profiles further render them promising candidates for early non-invasive diagnosis and prognostic monitoring [11]. In regenerative medicine, exosomes exhibit significant value in promoting osteogenic differentiation, angiogenesis, and immune microenvironment modulation, owing to their low immunogenicity, excellent ability to cross biological barriers, and endogenous pro-regenerative potential [12].
In recent years, research on exosomes in OS has progressively deepened, expanding from basic mechanistic exploration to multiple directions, including diagnostic marker development, biotherapeutic carrier design, and bone tissue engineering applications [13]. Exosomes not only serve as liquid biopsy markers to enhance early detection and prognostic stratification accuracy, but also act as natural nanocarriers for precision biotherapy [14]. Furthermore, they can be combined with biomaterials to achieve synergistic anti-tumor and tissue-repair effects, offering a promising avenue for integrated strategies that combine anti-tumor therapy with postoperative functional reconstruction [15]. To date, no comprehensive synthesis has systematically linked exosome functions across the entire OS clinical workflow, from early diagnosis to anti-tumor therapy and postoperative functional reconstruction. Firstly, many studies have focused on the mechanisms underlying tumor formation, metastasis, and drug resistance, with little attention paid to how exosomes can be integrated as tools for dynamic monitoring within clinical practices [13,16,17]. Secondly, most studies address either the anti-tumor effects of exosomes or their role in promoting bone regeneration, as it is difficult to distinguish between the dual functions of these exosomes; one of the potential adverse effects of certain exosomes is the exacerbation of malignant tumors [18]. Table 1 provides reviews of osteosarcoma and exosomes and their role in this review’s argument. In contrast, the present review uniquely integrates exosome functions across the entire OS clinical workflow—from early diagnosis and therapeutic intervention to post-surgical bone regeneration—providing a unified framework that bridges oncology, immunology, and tissue engineering, rather than treating these dimensions separately. This comprehensive perspective distinguishes our work from recently published reviews and aims to offer a more holistic theoretical foundation for future research and clinical translation.
Table 1.
Reviews of osteosarcoma and exosomes and their role in this review’s argument.
| Core content summarized | Role in the review’s argument | Reference |
|---|---|---|
| Establishes the unique bimodal age distribution of osteosarcoma, affecting adolescents and older adults, defining the patient population | Clinical Rationale: Defines the disease burden and target demographic, underscoring the need for tailored therapeutic strategies | [1] |
| Describes the multidisciplinary model (neoadjuvant chemotherapy, surgery, adjuvant chemotherapy) as the established standard of care | Clinical Baseline: Sets the benchmark for current therapy against which new strategies must be measured | [2] |
| Reports the plateaued 5-year overall survival rate of 60–70% for localized OS achieved with current standard regimens | Clinical Progress and Bottleneck: Highlights significant but stagnant progress, establishing the need for novel approaches to break this plateau | [3] |
| Documents the lack of survival improvement over 2 decades, particularly for metastatic or relapsed/refractory OS | Unmet Clinical Need: Identifies the critical patient subgroups with the most urgent requirement for new therapeutic modalities | [4,5] |
| Identifies chemotherapy resistance and the “cold” (immunologically inert) tumor microenvironment as major obstacles limiting efficacy | Biological Rationale: Defines the specific pathophysiological barriers that novel therapies (like exosomes) must overcome | [6] |
| Describes the functional and structural deficits (bone/soft tissue defects, disrupted microenvironment) resulting from radical tumor resection | Surgical Challenge: Articulates the reconstruction imperative, providing the rationale for a combined anti-tumor and pro-regenerative approach | [7,8] |
| Defines exosomes as lipid-bilayer vesicles (30–150 nm) from diverse cellular sources, serving as natural intercellular messengers | Foundation of Exosome Biology: Introduces exosomes as a platform technology, highlighting their natural origin and stability | [9] |
| Details the bioactive cargo (proteins, lipids, miRNAs, lncRNAs) that mediate directed regulation of recipient cell function | Mechanistic Basis: Explains how exosomes exert their effects, linking their structure to their functional capacity | [10] |
| Enumerates exosome involvement in OS pathogenesis: proliferation, invasion, pre-metastatic niche formation, immune escape, chemoresistance, and their biomarker potential | Oncological Role: Systematically summarizes the tumor-promoting and diagnostic aspects, which are crucial to understand for developing therapeutic interventions | [11] |
| Highlights exosome advantages (low immunogenicity, barrier penetration) and their value in promoting osteogenesis, angiogenesis, and immune modulation | Regenerative Role: Summarizes the tissue-repair capabilities, providing the biological plausibility for bone regeneration | [12] |
| Notes the expansion of research from basic mechanisms to diagnostic markers, biotherapeutic carriers, and bone tissue engineering | Research Trajectory: Demonstrates the field’s growth and the natural progression towards integrated applications | [13] |
| Positions exosomes as tools for early detection and prognostic stratification, enhancing diagnostic precision | Diagnostic Application: Supports the use of exosomes beyond therapy, as dynamic monitoring tools | [14] |
| Highlights the combination of exosomes with biomaterials to achieve a synergy of anti-tumor therapy and tissue repair | Translational Strategy: Introduces the concept of integrated delivery systems, the core innovation of the review’s proposed framework | [15] |
| Critiques that most studies concentrate on tumor mechanisms, with limited attention to integrating exosomes as dynamic clinical monitoring tools | Identification of Gap 1: Points out the disconnect between mechanistic research and clinical application, justifying the review’s clinical translation perspective | [16,17] |
| Identifies a gap where studies focus on either anti-tumor or pro-regenerative effects separately, while certain exosomes may paradoxically exacerbate malignancies | Identification of Gap 2: Highlights the unresolved duality and safety concerns, establishing the need for a balanced, integrative framework | [18] |
This review is specifically designed as a cross-domain integrative synthesis that bridges tumor biology and orthopedic regenerative medicine. Its core contribution is to propose and elaborate the concept of “exosome-mediated integrated strategy for anti-tumor therapy and bone regeneration” for OS. We primarily synthesize preclinical evidence, biomarker development data, and tissue engineering advances published over the past 5 years, with a particular focus on exosome-biomaterial composite systems that simultaneously address residual tumor eradication and large segmental bone defect repair. This article aims to review the roles of osteosarcoma-derived exosomes in tumor progression, chemoresistance, and bone regeneration, as well as their potential for drug delivery.
Osteosarcoma
Epidemiological Characteristics of OS
OS is the most common primary malignant bone tumor, with an incidence rate of approximately 3–5 per million population. Despite its relatively low overall incidence, OS is associated with extremely high malignancy, characterized by strong biological invasiveness and a propensity for early hematogenous metastasis [19]. Epidemiologically, the disease exhibits a typical bimodal age distribution: the primary incidence peak occurs in adolescents during the period of rapid skeletal growth, with the highest prevalence between 10 and 14 years of age; the secondary peak is observed in adults aged over 60 years, mostly secondary to bone metabolic abnormalities such as Paget’s disease or a history of prior radiotherapy. Moreover, the incidence rate is slightly higher in males than in females [20]. The predilection sites of OS are highly concentrated in the metaphyses of long bones of the extremities, with the distal femur, proximal tibia, and proximal humerus being the most common. Approximately 15%–20% of patients present with distant metastases, predominantly in the lungs, at the time of initial diagnosis [21,22]. Together with the presence of chemoresistance, these factors serve as key determinants influencing patient prognosis. Furthermore, gene mutations (eg, TP53 and RB1), bone-related underlying diseases, and iatrogenic exposure are all recognized as important risk factors for OS development [23–25].
Current Status of OS Treatment
The clinical management of OS currently remains centered on multidisciplinary comprehensive therapy, with the standard regimen being neoadjuvant chemotherapy combined with surgical resection and adjuvant chemotherapy [26]. Chemotherapy primarily relies on the classic MAP combination regimen, consisting of high-dose methotrexate, doxorubicin, and cisplatin [27]. This regimen effectively controls micrometastases, improves surgical resectability, and has facilitated the gradual replacement of traditional amputation with limb-sparing surgery as the mainstream surgical approach, stabilizing the 5y-OSurv of patients with localized OS at 60%–70% [28]. Despite the maturity of this 3-stage standardized comprehensive treatment, the overall patient survival rate has plateaued over the past 2 decades. Additionally, chemoresistance remains an unresolved challenge, and OS exhibits low sensitivity to radiotherapy, which is only indicated as adjuvant therapy for inoperable cases or local disease control. The 5y-OSurv for patients presenting with de novo metastasis or relapsed/refractory disease remains below 30% [4,29].
To address these clinical bottlenecks, emerging therapeutic strategies such as anti-angiogenic targeted agents (multi-target tyrosine kinase inhibitors) and immunotherapy have become focal points of current research [30,31]. However, OS is characterized by a “cold tumor” microenvironment with sparse immune cell infiltration, leading to limited efficacy of single-agent immune checkpoint inhibitors. No standardized treatment regimen has been established for these therapies, and there is a lack of clear second-line treatment standards for relapsed and refractory OS [32]. Therefore, in-depth investigation of the synergistic mechanisms between targeted drugs and immunotherapy, development of novel cellular therapeutic technologies such as chimeric antigen receptor T (CAR-T) cell therapy, and active advancement of clinical trials have become critical directions in translational medicine to overcome the therapeutic challenges of OS [33].
Following comprehensive treatment of OS, large and complex bone and soft tissue defects often occur, accompanied by disruption of the local bone microenvironment [34]. Thus, effective bone defect reconstruction and maintenance of orderly bone tissue regeneration post-treatment are not only essential for filling anatomical gaps and restoring limb mechanical stability and motor function, but also constitute the core of successful limb-sparing surgery, with significant clinical implications for improving patient prognosis [35]. The primary goal of this process is to promote high-level biological integration and vascularization of implants or bone grafts with host bone. Structural reconstruction (eg, prosthesis or biomaterial implantation) prevents functional impairments such as pathological fractures and prosthesis loosening, while biological regulation re-establishes a normal bone metabolic microenvironment, facilitates the coupling of osteogenesis and angiogenesis, and reduces the risk of long-term complications including infection and nonunion [36]. Furthermore, maintaining orderly bone regeneration can mitigate abnormal microenvironmental signals associated with tumor recurrence, serving as a cornerstone for maximizing limb function preservation, reducing disability rates, enabling young patients to return to normal social activities, and thereby comprehensively enhancing their long-term quality of life and mental health [37].
Exosomes
Definition and Basic Characteristics of Exosomes
Exosomes are a class of extracellular vesicles with a lipid bilayer structure that are actively secreted by cells through the endocytic pathway [38,39]. The content of membrane lipid components (eg, cholesterol and ceramide) in the plasma membrane, endoplasmic reticulum, and endosomal membranes significantly influences the size and cargo of exosomes [40], with diameters ranging from 30 to 150 nm [41]. Exosomes are widely present in various body fluids, such as blood, urine, saliva, cerebrospinal fluid, amniotic fluid, and malignant ascites [42]. In basic medical research, they are typically named based on their cellular origin.
The membrane structure of exosomes is enriched in specific protein markers, including members of the tetraspanin superfamily (CD9, CD63, CD81), heat shock proteins (HSP70, HSP90), Endosomal Sorting Complex Required for Transport (ESCRT)-associated proteins, and Rab GTPases [43]. Their lumen harbors proteomic, lipidomic, and nucleomic information derived from their parental cells. Among the RNA components, miRNAs account for the highest proportion (65%–90%), followed by messenger RNAs (mRNAs, 5%–15%), lncRNAs (1%–10%), and a small quantity of circular RNAs (circRNAs) [44]. Therefore, exosomes can act as carriers for intercellular communication, transferring these molecules from one cell to another via autocrine, paracrine, and endocrine pathways, thereby mediating information exchange and functional regulation between cells and organs [45].
Classical and Non-Classical Biogenesis Pathways of Exosomes
Classical exosome biogenesis begins with plasma membrane inward budding to form early endosomes [46]. Subsequently, the endosomal membrane invaginates under the ESCRT complex (ESCRT-0, -I, -II, -III) [47–50] and accessory proteins including VPS4 ATPase and ALIX [40], generating a multivesicular body (MVB) containing intraluminal vesicles (ILVs). Upon MVB–plasma membrane fusion, ILVs are released as exosomes. Beyond this canonical route, non-classical pathways originate from nuclear membranes, mitochondria, autolysosomes, and autophagosomes. Nuclear membrane-derived exosomes depend on neutral sphingomyelinase 1 (nSMase1)-mediated ceramide production, which triggers LTB4 synthase aggregation, FLAP and ALIX recruitment, and vesicle scission [51]. Mitochondrial sources yield 2 forms: Mitovesicles—double-membrane vesicles lacking tetraspanins and plasma membrane components, yet carrying mitochondrial DNA, RNA, proteins, and lipids without TOMMs or ribosomes [52]—which bud from mitochondrial subcompartments and either enter the cytoplasm or fuse with MVBs for extracellular release [53]; and mitochondrial cargo-enriched exosomes (mt-enREXOs), formed when autophagosomes capture damaged mitochondria and fuse with maturing MVBs, loading mitochondrial components into exosomes via an amphisome-like hybrid organelle, followed by MVB–plasma membrane fusion [54]. Additionally, autolysosomes can directly fuse with the plasma membrane to secrete contents—a process termed secretory autophagy [55]. These alternative routes expand the functional repertoire of exosomes beyond the classical ESCRT-dependent machinery.
It is worth noting that at present, the debate on the molecular mechanism of exosomes production has not stopped. A typical example is that GW4869, as a “gold standard” tool drug for inhibiting exosomes production, is widely considered to block the production of exosomes independent of ESCRT by inhibiting neutral sphingomyelinase (nSMase2). However, a study in 2024 found that nSMase2 was not necessary for exosomes production by constructing knockout mice, which challenged the traditional view that lasted for many years and pointed out that GW4869 might have a serious off-target effect [56]. Therefore, we believe that the core problem at present is the uncertainty of our commonly used tools and research models, which makes it difficult to align the conclusions of different studies. The key to solving the debate on the molecular mechanism of exosomes is to shift from relying on indirect evidence and pharmacological tools to using more rigorous genetic models and systematic research methods.
Uptake and Degradation Pathways of Exosomes
After exosomes escape degradation via fusion with lysosomes [41], they are recognized and internalized by recipient cells primarily through the following mechanisms: (1) Membrane fusion: Exosomes can directly fuse with the plasma membrane of recipient cells, releasing their cargo into the cytoplasm. This is the most direct mode of cargo delivery, albeit with relatively low efficiency [57]. (2) Receptor-mediated endocytosis is the predominant uptake pathway. Ligands on the exosomal surface (eg, tetraspanins, integrins, lectins) bind to specific receptors on the recipient cell membrane, triggering either clathrin-dependent or clathrin-independent endocytosis. Studies have demonstrated that a substantial fraction of exosomal contents are “externally localized”—a feature that dictates the selectivity of exosome uptake, in which recipient cells are more prone to internalizing a particular type of exosome [58]. (3) Phagocytosis and macropinocytosis: Immune cells (eg, macrophages, dendritic cells [DCs]) can take up larger exosome clusters through phagocytosis [59], while macropinosomes formed by plasma membrane ruffling can also non-specifically internalize exosomes [60].
Phosphatidylserine exposed on the exosomal surface serves as a critical signal for phagocyte recognition and clearance of exosomes [61]. In the systemic circulation, exosomes exhibit a relatively short half-life. Macrophages in the liver and spleen are the primary sites responsible for clearing circulating exosomes [62]. Additionally, exosomes can be excreted into the urine via renal filtration [63].
However, at present, there are still disputes about the hypothesis of exosomes’ endocytosis-escape and whether exosomes choose functional delivery or degradation [64]. We think this is because most of the evidence mainly comes from cell experiments in vitro, and there is no more rigorous experimental evidence that can prove that this process really happens in vivo.
Exosomes in the Regulation of Tumor Oncogenesis and Progression
Exosomes and Tumor Cell Proliferation
Tumor-derived exosomes (TEXs) directly promote tumor cell proliferation through multiple mechanisms. First, oncogenic proteins (eg, EGFRvIII, mutant KRAS) and miRNAs (eg, miR-21, miR-155) carried by TEXs can be internalized by adjacent tumor cells, thereby activating pro-proliferative signaling pathways such as PI3K/AKT and MAPK/ERK [65]. Second, enzymes encapsulated within TEXs can effectively degrade the physical barrier of the extracellular matrix, thereby creating a microenvironment that favors tumor cell proliferation [66]. Lastly, TEXs activate cancer-associated fibroblasts (CAFs), which then secrete growth factors and cytokines to further stimulate tumor growth [67]. In addition to this paracrine mechanism, TEXs directly promote tumor cell proliferation by inducing angiogenesis and enhancing the vascular supply to the tumor.
Exosomes and Tumor Metastasis and Invasion
Tumor-derived exosomes (TEXs) drive metastasis through 3 coordinated steps: angiogenesis, epithelial–mesenchymal transition (EMT), and pre-metastatic niche (PMN) formation. First, TEXs deliver pro-angiogenic factors (VEGF, FGF, PDGF) and miRNAs (miR-210, miR-135b) to stimulate endothelial cell migration [68], while TEX-activated Wnt signaling further promotes angiogenesis [69]. Hypoxic tumor cells secrete exosomes enriched in these factors, exacerbating vascular network formation [70]. Second, TEXs induce EMT by transporting TGF-β, miR-200 family members, and integrins, which activate EMT transcription factors (Snail, Slug, ZEB1/2), downregulate epithelial markers (E-cadherin) and upregulate mesenchymal markers (N-cadherin, vimentin) [71,72]. This loss of cell–cell junctions confer migratory and invasive capabilities, initiating the metastatic cascade. Third, TEXs establish PMNs in distant organs before tumor cell arrival. Through systemic circulation, they remodel local microenvironments via integrins (eg, ITGαvβ5, ITGα6β4) that determine organ-specific metastasis [43]. In target organs, TEXs convert hostile niches into tumor-supportive “soil” by upregulating fibronectin, recruiting bone marrow-derived cells, activating resident fibroblasts, and increasing vascular permeability [73]. Collectively, these exosome-mediated mechanisms create a permissive route for OS dissemination.
Exosomes and Tumor Immunity
Exosomes exert dual immune functions—both stimulatory and suppressive. On the stimulatory side, they carry MHC-I and MHC-II molecules to present tumor antigens to T cells [74], while heat shock proteins act as adjuvants promoting dendritic cell (DC) maturation and cross-presentation [75]. Immune cell-derived exosomes offer safer cell-free immunotherapy alternatives: CAR-T exosomes retain antigen specificity and cytotoxicity without proliferation risks [76], and DC-derived exosomes rich in co-stimulatory molecules have entered trials as tumor vaccines [77].
Conversely, tumor-derived exosomes (TEXs) drive immune escape by reprogramming the tumor microenvironment. They polarize macrophages towards the immunosuppressive M2 phenotype, secreting IL-10 and TGF-β [78]; deliver TGF-β and NKG2D ligands to impair natural killer (NK) cell cytotoxicity [79]; interfere with DC maturation and antigen presentation [40]; expand myeloid-derived suppressor cells (MDSCs) that inhibit T cells via arginase 1 and iNOS [80]; and surface-express PD-L1 that binds PD-1 on T cells, inducing exhaustion and apoptosis [81]. Additionally, TEX-borne TGF-β and miR-21 suppress T cell proliferation and promote regulatory T cell expansion [81]. This bifunctional nature positions exosomes as both potential immunotherapeutics and key mediators of tumor immune evasion.
Exosomes and Tumor Metabolism
Metabolic reprogramming—a core cancer hallmark—is potently mediated by tumor-derived exosomes (TEXs), which deliver enzymes, non-coding RNAs, and metabolites to remodel glycolysis, lipid metabolism, amino acid flux, and mitochondrial function in recipient cells, thereby supporting tumor nutrition, immune evasion, and therapy resistance. In glucose metabolism, TEXs carry glycolytic enzymes (PKM2, LDHA) and regulatory miRNAs (miR-122, miR-155) to drive aerobic glycolysis (Warburg effect), supplying biosynthetic precursors while generating lactate that acidifies the tumor microenvironment and promotes immunosuppression and metastasis [82–84]. In lipid metabolism, TEXs transfer CD36, FABP, and lipid synthesis enzymes to activate fatty acid oxidation and synthesis, conferring metabolic flexibility under nutrient stress and chemotherapeutic pressure, thus enabling resistance acquisition [85–88]. In amino acid and mitochondrial metabolism, exosomal metabolites and miRNAs regulate glutaminolysis and serine synthesis [89,90]; moreover, TEXs transfer functional mitochondrial components—including intact mitochondria—to enhance recipient cell bioenergetics and oxidative capacity [91]. Collectively, exosome-driven metabolic rewiring orchestrates a multifaceted adaptive response that fuels tumor progression and therapeutic failure.
The regulatory roles of exosomes in tumorigenesis and progression are illustrated in Figure 1.
Figure 1. The major biological processes of the exosomes encourage tumor invasion, proliferation, metastasis and regulate tumor immune environment and metabolism.

Exosomes produced by tumors transport carcinogens to promote the secretion of VEGF/FGF from blood vessels around tumors, activate fibroblasts and drive proliferation. By down-regulating E-cadherin, they induce EMT and pseudopodia, promote metastasis and PMN formation. Metabolically, they carry PKM2/miRNAs to regulate glycolipid signals and lead to lactic acid accumulation. In immunology, TDEs triggers PD-1: PD-L1 depletion of T cells, and polarizes macrophages into M2 phenotype through MHC-mediated DC-T cell interaction, thus establishing a deep immunosuppression environment. VEGF, Vascular Endothelial Growth Factor; FGF, Fibroblast Growth Factor; EMT Transition, Epithelial-to-Mesenchymal Transition; PMN formation, Pre-metastatic Niche formation; PKM2, Pyruvate Kinase M2; HSP, Heat Shock; Proteins PD-L1, Programmed Death-Ligand 1. ↑ indicates an increase in expression. ↓ indicates a decrease in expression. The picture was originally created by us, and the research drawing software of Nano Banana and AI was applied.
The Role of Exosomes in OS
The Role of Exosomes in OS Oncogenesis and Progression
Exosome-mediated intercellular communication plays a central regulatory role in the oncogenesis, progression, and TME remodeling of OS. Exosomes derived from OS cells can induce the transformation of mesenchymal stem cells toward a pro-tumorigenic phenotype and activate endothelial cells to promote angiogenesis, thereby providing microenvironmental support for tumor proliferation [92]. Meanwhile, they can enhance the migratory and invasive capacities of tumor cells by promoting EMT and, by virtue of their significant lung tropism, induce fibroblast activation, remodel the immune microenvironment, and increase vascular permeability in the distal lungs to construct a pre-metastatic niche, which is an important biological basis for early lung metastasis of OS [11,93]. In addition, miRNAs such as miR-21 and miR-25 carried by exosomes can promote tumor cell proliferation and anti-apoptosis, while miR-143 and other miRNAs exhibit certain tumor-suppressive effects, reflecting the functional diversity of exosomes in OS regulation [94,95].
At the molecular level, exosomes primarily drive the malignant progression of OS by delivering non-coding RNAs (miRNAs, lncRNAs, circRNAs) to precisely regulate canonical signaling pathways, including PI3K/AKT, Wnt/β-catenin, MAPK, and TGF-β [96,97]. For instance, exosomal miRNAs can activate the PI3K/AKT pathway by targeting PTEN or modulate the Wnt/β-catenin pathway to sustain tumor stemness [98]. Exosomes also play a pivotal role in OS immune escape and chemoresistance [5,99]: they can mediate the formation of an immunosuppressive microenvironment by regulating immune cell polarization and inhibiting T cell function, and achieve horizontal transmission of drug-resistant phenotypes by transporting P-glycoprotein and drug resistance-related miRNAs, thereby reducing the therapeutic efficacy of first-line agents such as methotrexate and cisplatin. In summary, exosomes participate in the malignant progression of OS through a dual model of “substance transport-signal regulation”, which not only provides a key entry point for elucidating the mechanisms of disease progression but also offers an important research direction for the development of novel liquid biopsy markers and targeted delivery therapeutic systems. Table 2 shows exosomes miRNAs, lncRNAs, circRNAs and protein related to the progression of osteosarcoma, and their biological functions and supporting evidence.
Table 2.
Exosomes miRNAs, lncRNAs, circRNAs and protein related to the progression of osteosarcoma, and their biological functions and supporting evidence.
| Molecular cargo | Key examples cited | Biological functions in OS pathogenesis | Supporting evidence and mechanistic pathways (ref.) |
|---|---|---|---|
| miRNAs | miR-21, miR-25 | Promote tumor cell proliferation and anti-apoptosis, contributing to tumor growth and survival | Functional diversity of exosomal miRNAs in OS regulation, with oncogenic and tumor-suppressive roles [94,95] |
| miR-143 | Exhibits tumor-suppressive effects, counterbalancing the oncogenic drivers | Functional diversity of exosomal miRNAs in OS regulation [94,95] | |
| miRNAs (eg, targeting PTEN, Wnt/β-catenin modulators) | Activate PI3K/AKT pathway (via PTEN targeting) and sustain tumor stemness (via Wnt/β-catenin modulation) | Precise regulation of canonical oncogenic signaling pathways, including PI3K/AKT and Wnt/β-catenin [98] | |
| Drug resistance-related miRNAs | Horizontally transfer chemoresistance phenotypes, reducing efficacy of first-line agents (eg, methotrexate, cisplatin) | Mediate horizontal transmission of drug-resistant phenotypes; key mechanism in OS chemoresistance [5,99] | |
| lncRNAs | Function as key regulators in signaling pathways (PI3K/AKT, Wnt/β-catenin, MAPK, TGF-β) that drive malignant progression | Exosomal non-coding RNAs (including lncRNAs) drive OS progression by precisely regulating canonical signaling pathways [96,97] | |
| circRNAs | Function as key regulators in signaling pathways (PI3K/AKT, Wnt/β-catenin, MAPK, TGF-β) that drive malignant progression | Exosomal non-coding RNAs (including circRNAs) drive OS progression by precisely regulating canonical signaling pathways [96,97] | |
| Proteins | P-glycoprotein (P-gp) | Transports P-glycoprotein to mediate horizontal transfer of multidrug resistance, reducing chemosensitivity | Key mechanism in OS chemoresistance [5,99] |
Exosomes for Early Diagnosis of OS
With advantages of high stability in body fluids, carriage of tumor-specific molecular profiles, and ease of non-invasive acquisition, exosomes have emerged as a novel diagnostic vector with considerable translational potential in OS liquid biopsy. Relevant research has progressed from single-marker screening to multi-marker combined diagnosis and clinical efficacy validation [14]. Existing studies have confirmed by clinical samples that bioactive molecules (miRNAs, lncRNAs, circRNAs, and proteins) encapsulated in OS cell-derived exosomes exhibit characteristic expression profiles in patients’ serum or plasma, which can serve as potential diagnostic markers to differentiate OS patients from healthy individuals and those with benign bone diseases [100]. For example, exosomal miR-21, miR-25, and miR-429 are significantly upregulated in OS patients, whereas tumor-suppressive miRNAs such as miR-143 and miR-101 are markedly downregulated [101]. COX4I2, the regulatory subunit of mitochondrial respiratory chain complex IV, is up-regulated in the tumor microenvironment. After being delivered to OS, it can inhibit iron death by reducing intracellular Fe2+ level and ROS accumulation, thus enhancing the proliferation ability and mitochondrial integrity of tumor cells and promoting tumor growth [102]. Annexin II can be used as a marker to distinguish the chemosensitivity of OS [103]. The levels of exosomal proteins such as PD-L1 and N-cadherin are closely associated with tumor invasion, lung metastasis risk, and prognostic stratification [104]. Meanwhile, the rapid development of novel detection technologies—including microfluidic separation, surface-enhanced Raman spectroscopy, electrochemical sensing, and machine learning-assisted identification—has further improved the sensitivity and specificity of exosome detection [105,106]. It is worth noting that the anatomical separation of the bone tissue-bone-blood barrier does not prevent the representation of extracellular vesicles from primary bone tumors. Recent studies have completely overturned the traditional view that bones are merely passive support structures; bones can actively regulate the metabolism and function of distant organs by secreting various bioactive factors such as osteocalcin (OCN) and fibroblast growth factor 23 (FGF23) [107,108]. This indicates that bones are not closed systems, and there are anatomical and physiological mechanisms for substance exchange within them. Secondly, a growing body of evidence from cell-based and animal studies has demonstrated the clinical potential of combined exosome detection strategies not only avoids the problem of low diagnostic accuracy of OS from a single source, but also provides new treatment monitoring and prognostic evaluation of the disease [109]. It is precisely because of these advantages that, compared with the traditional serum markers (eg, ALP, LDH) and CT imaging methods for diagnosing OS, the emerging exosome biomarkers are irreplaceable. Traditional serum markers have low sensitivity and specificity, and are influenced by various physiological and pathological factors. Although CT and other imaging methods can directly and accurately display the location and size of tumor and its relationship with surrounding tissues, there is a risk of radiation exposure. The ability to judge early tiny lesions and residual active tumor cells after chemotherapy is limited. However, the emerging exosome biomarkers can be used for early diagnosis, dynamic monitoring, and reflection of tumor heterogeneity, and are non-invasive/minimally invasive liquid biopsy, which can be sampled repeatedly, carrying complex information about the tumor and microenvironment.
Despite their significant application prospects in OS diagnosis, the clinical translation of exosomes still faces a series of key technical challenges and standardization issues [110]. First, there is no consensus on exosome isolation and purification methods. Ultracentrifugation, precipitation, chromatography, and microfluidic technologies exhibit significant differences in recovery rate, purity, and time efficiency. For example, the polymer precipitation method yields high quantities of extracellular vesicles, but the purity is low, and it tends to result in the co-precipitation of many non-extracellular vesicle impurities. The immune affinity capture method produces fewer extracellular vesicles but with higher purity and it is antibody-dependent [111]. Size exclusion chromatography, on the other hand, helps to preserve the structure and biological activity of extracellular vesicles [112]. Additionally, interference from impurities such as plasma lipoproteins and cell debris often leads to poor reproducibility of detection results [113]. Second, the detection process lacks standardized operating procedures: sample collection type, anticoagulant selection, storage conditions, and preprocessing methods all affect the stability of exosomes and their contents, making cross-laboratory data comparison difficult [114]. Additionally, the diagnostic efficacy of single exosome markers is limited, as they are easily influenced by individual differences, comorbidities, and therapeutic interventions, and no recognized diagnostic thresholds or interpretation criteria have been established [115,116]. Therefore, future research urgently needs to establish standardized systems for exosome isolation, quality control, and quantification; promote multi-center, large-sample clinical cohort validation; screen and optimize a combined diagnostic panel consisting of multiple RNA and protein molecules; and construct efficient diagnostic models integrated with artificial intelligence algorithms. This will facilitate the smooth transition of exosome detection technology from basic research to precise clinical diagnosis of OS.
Exosomes for OS Biotherapy
With low immunogenicity, excellent biocompatibility, and efficient delivery capacity across biological barriers, exosomes have become a highly promising novel functional carrier and regulatory tool in OS biotherapy. Relevant research is gradually advancing from basic mechanism exploration to engineering applications and preclinical translation [117]. This concept has been extensively validated in both cell-based and animal experiments. As natural nanocarriers, exosomes can be loaded with chemotherapeutic agents (eg, doxorubicin, cisplatin) and nucleic acid molecules (eg, miR-143, miR-101, siRNA) via electroporation, co-incubation, or other approaches [118], enabling targeted delivery and regulation of key signaling pathways such as PI3K/AKT and Wnt/β-catenin—enhancing tumor-killing efficacy while reducing systemic toxic and adverse effects. Surface engineering modification with (DSS)6 bone-targeting peptides, aptamers, RGD peptides, or other moieties can further improve their specific homing ability to OS cells, achieving precise drug delivery [119]. Exosomes also play important roles in reversing chemoresistance, inhibiting angiogenesis, and blocking bone destruction: they can reduce drug resistance by delivering drug resistance-regulating molecules and inhibiting VEGF and MMPs pathways [120]. Osteoblast-derived exosomes can also induce the differentiation of OS cells into mature osteoblasts by regulating the URG4/Wnt pathway [121], providing new insights for differentiation therapy. However, there is no research on using exosomes directly in the animal model of bone reconstruction after OS, because exosomes are contradictory in killing tumor cells at the same time and promoting new bone formation. In the OS environment, exosomes released by tumor cells themselves are usually “cancer-promoting”, which will promote tumor progression, metastasis and drug resistance. If these exosomes are directly used in bone defects, there is theoretically a risk of stimulating the recurrence of residual tumors. Although exosomes derived from mesenchymal stem cells (MSC) show good ability to promote bone regeneration, recent studies have also pointed out that exosomes are a “double-edged sword” in regulating the development of OS, which can not only inhibit tumors, but also aggravate the disease through various mechanisms [122]. Therefore, we believe that the engineering remodeling of exosomes can simultaneously solve the problems of anti-tumor and promoting bone regeneration, and separate and coordinate these 2 functions in time and space.
At the level of immunotherapy and cell therapy, the role of exosomes has expanded from a simple delivery carrier to a functional immune regulatory mediator [117,122]. DC-derived exosomes can activate CD8 T cells to mediate specific anti-tumor immunity by carrying tumor antigen peptides and MHC molecules; macrophage- and bone marrow mesenchymal stem cell (BMSC)-derived exosomes can remodel the TME and enhance NK cell cytotoxicity, with combination with immune checkpoint inhibitors further improving anti-tumor efficacy [123,124]. Genetically modified BMSC exosomes can stably load tumor-suppressive miRNAs to directly inhibit tumor proliferation and migration [125]. In addition to exosomes derived from immune cells, which can exert antitumor effects by activating the activity of immune cells, exosomes originating from oncolytic viruses, along with the complexes formed when they combine with exosomes, can invade tumor cells specifically. They utilize the resources within these tumor cells to replicate rapidly, producing thousands of new viruses. This leads to the tumor cells bursting like balloons and dying, while simultaneously releasing a new generation of viruses that go on to infect surrounding tumor cells. Moreover, when tumor cells are destroyed, tumor-specific antigens are released, which activate immune cells such as T cells to identify and eliminate tumor cells throughout the body [126,127]. Artificial exosomes and exosome-mimetic nanoparticles combine the homing properties of natural vesicles with the drug-loading advantages of synthetic materials, providing a novel therapeutic platform for relapsed and metastatic OS [128]. Although exosomes show significant application potential in OS biotherapy, key issues—including large-scale preparation, quality control standardization, in vivo delivery efficiency, and long-term safety—remain unresolved. In the future, relying on multi-center preclinical validation and precise engineering modification, exosomes will be further advanced from basic research to clinical translational application. The main signal pathways and functions of exosomes in the treatment of osteosarcoma in Table 3. The roles of exosomes in OS oncogenesis, diagnosis and therapy are summarized and illustrated in Figure 2.
Table 3.
The main signal pathways and functions of exosomes in the treatment of osteosarcoma.
| Therapeutic strategy/cargo | Key signaling pathways targeted | Therapeutic effects and mechanisms in OS | Supporting evidence and ref. |
|---|---|---|---|
| Chemotherapeutic Agents (Doxorubicin, Cisplatin) | PI3K/AKT, Wnt/β-catenin | Loaded via electroporation/co-incubation for targeted delivery; enhances tumor-killing efficacy while reducing systemic toxicity | Exosomes as natural nanocarriers for chemo-drug delivery [119] |
| Tumor-Suppressive miRNAs (miR-143, miR-101, siRNA) | PI3K/AKT, Wnt/β-catenin | Regulate key oncogenic pathways to inhibit tumor proliferation and migration; reverses malignant phenotypes | Nucleic acid delivery via exosomes for targeted pathway modulation [119] |
| Surface-Engineered Exosomes (DSS6, aptamers, RGD peptides) | - | Improves specific homing to OS cells; achieves precise drug delivery and reduces off-target effects | Surface engineering for enhanced tumor targeting [120] |
| Exosomes Loaded with Drug Resistance-Regulating Molecules | VEGF, MMPs | Reverses chemoresistance; inhibits angiogenesis and bone destruction through VEGF/MMP pathway blockade | Exosome-mediated reversal of drug resistance and microenvironment remodeling [121] |
| Osteoblast-Derived Exosomes | URG4/Wnt pathway | Induces OS cell differentiation into mature osteoblasts; provides a novel differentiation therapy strategy | Regulation of URG4/Wnt pathway for differentiation therapy [122] |
| Engineered MSC-Exosomes with Tumor-Suppressive miRNAs | PI3K/AKT, Wnt/β-catenin, MAPK, TGF-β | Genetically modified BMSC exosomes stably load therapeutic miRNAs; directly inhibits tumor proliferation and migration | Genetically engineered exosomes for stable miRNA delivery [126] |
| DC-Derived Exosomes (carrying tumor antigens/MHC) | Immune checkpoint pathways | Activates CD8+ T cells to mediate specific anti-tumor immunity; enhances T-cell mediated killing | Immunotherapeutic role of exosomes in OS [124,125] |
| Macrophage/BMSC-Derived Exosomes | Immune checkpoint pathways | Remodels TME; enhances NK cell cytotoxicity; synergizes with immune checkpoint inhibitors to improve efficacy | Immune cell-derived exosomes for TME remodeling and combination immunotherapy [124,125] |
| Oncolytic Virus-Derived Exosomes and Complexes | - | Specifically invades tumor cells; replicates to produce new viruses, inducing oncolysis and releasing tumor antigens to activate systemic T-cell responses | Oncolytic virus-exosome complexes for lytic and immune-activating therapy [127,128] |
| Artificial Exosomes and Exosome-Mimetic Nanoparticles | - | Combines natural homing properties with synthetic material drug-loading advantages; platform for relapsed/metastatic OS | Synthetic exosome-mimetics for advanced therapeutic platforms [129] |
| Key Challenges and Future Directions | - | Large-scale preparation, quality control, in vivo delivery efficiency, and long-term safety remain unresolved; requires multi-center preclinical validation and precise engineering | Translational hurdles and future perspectives for exosome-based OS therapy [118,123] |
Figure 2. The role of exosomes in the oncogenesis, diagnosis and biotherapy of osteosarcoma.

TDEs activate PI3K/AKT and WNT/β-catenin pathways, promoting metastasis and lung pre-metastatic niche formation via fibroblast activation, driven by oncogenic miR-21/miR-25 while suppressing miR-143. For diagnosis, circulating exosomes enable early detection via microfluidics, SERS sensors, and AI analysis. Therapeutically, engineered exosomes deliver RGD-targeted doxorubicin and siRNA. Immunity is enhanced by dendritic cell-derived exosomes activating CD8+ T cells via MHC-I, while BMSC-derived exosomes inhibit OS proliferation and metastasis. PI3K/AKT, Phosphoinositide 3-kinase/Protein Kinase B, a key survival and proliferation pathway; WNT/β-catenin, Wingless-type MMTV integration site family/β-catenin, a canonical pathway driving malignant progression; Oncogenic miR-21, miR-25, microRNAs that promote cell proliferation and invasion; the Tumor-suppressive miR-143, a regulatory miRNA that inhibits OS growth; P-glycoprotein, a transmembrane ATP-binding cassette transporter; Surface-Enhanced Raman Scattering (SERS) sensor, a plasmonic nanosensor enabling ultra-sensitive fingerprint molecular detection; N-cadherin adhesion (a cell-matrix adhesion molecule indicating metastatic potential. The picture was originally created by us, and the research drawing software of Nano Banana and AI was applied.
Exosomes and Bone Regeneration
Molecular Mechanisms Underlying Exosome-Mediated Bone Regeneration
Comprehensive treatment of OS often results in large segmental bone defects and disruption of the local bone microenvironment; therefore, effective reconstruction of bone defects and maintenance of orderly bone regeneration are indispensable aspects of OS management. The extensive experimental studies described below demonstrate that exosomes can activate the osteogenic differentiation of stem cells by delivering osteogenic transcription factors and growth factors, induce the formation of a functional vascular network by delivering angiogenic factors, and deliver microRNAs that reprogram macrophages to facilitate bone remodeling. Thus, the multidimensional space-time coordination of osteogenic differentiation, osteogenic-angiogenesis coupling, immunomodulation, and osteoclast inhibition is the fundamental mechanism that promotes bone regeneration.
Induction and Promotion of Osteogenic Differentiation
Osteogenic differentiation refers to the process whereby undifferentiated mesenchymal stem cells gradually differentiate into osteoblasts capable of synthesizing and mineralizing the bone matrix under the regulation of specific signals [129]. Mounting evidence demonstrates that exosomes and the RNAs they carry (especially miRNAs and mRNAs) serve as core regulators of osteogenic differentiation both in vitro and in vivo. They influence this process by targeting specific signaling pathways in mesenchymal stem cells, osteoblasts, and other cell types [130]. However, exosomes derived from different cell sources exhibit unique functional characteristics in osteogenic regulation. Exosomes derived from BMSCs are enriched in various pro-osteogenic miRNAs, which promote the differentiation of BMSCs into osteoblasts by targeting and inhibiting negative regulators or activating positive signaling pathways [131]. miR-29a/29c-3p delivered by serum exosomes targets the DNA demethylase TET3, upregulates the DNA methylation level in the promoter region of Sox9 to epigenetically suppress Sox9 expression, and simultaneously inhibits the PI3K/AKT signaling pathway, ultimately facilitating the osteogenic differentiation of BMSCs [132]. Exosomes derived from M2-polarized macrophages carry miR-6879-5p to regulate TRIM26-mediated PKM ubiquitination, while promoting aerobic glycolysis and osteogenic differentiation of human periodontal ligament stem cells [133]. Additionally, exosomes can serve as natural delivery carriers for mRNAs. Engineered exosomes generated by co-transfection of BMP2 and Paip2 plasmids (with 8-fold higher Bmp2 mRNA loading and 3-fold higher BMP2 protein expression compared to native exosomes) initiate translation via internal ribosomal entry sites upon entering recipient cells, effectively bypassing inherent translational inhibition, driving sustained BMP2 protein expression, and significantly enhancing the osteogenic differentiation capacity of human BMSCs [134]. Fu et al demonstrated that BMSCs cultured in an in vitro biomimetic microenvironment that closely recapitulates the in vivo physiological milieu have significantly enhanced pro-osteogenic capacity of the derived exosomes [135].
Osteogenesis-Angiogenesis Coupling
Bone formation and angiogenesis are tightly coupled in space and time—blood vessels not only supply oxygen and nutrients to the nascent bone tissue but also promote osteogenesis via direct signal crosstalk between endothelial cells and osteoblasts. Studies have demonstrated that H-type blood vessels formed by endothelial cells exhibiting high expression of CD31 and endomucin (CD31hi Emcnhi ECs) play a pivotal role in bone regeneration [136]. BMSCs undergoing osteogenic differentiation can actively promote matched angiogenesis by dynamically regulating the miRNAs carried by exosomes, thereby achieving synergistic progression of osteogenesis and angiogenesis. For example, miR-150-5p expression is downregulated in exosomes secreted by BMSCs on day 7 of osteogenic differentiation (7D-BMSCs-exo); by upregulating SOX2 expression in endothelial cells, SOX2 overexpression further shifts the metabolic pattern of endothelial cells from oxidative phosphorylation to glycolysis, thereby inducing H-type blood vessel formation[137]. Furthermore, environmental stimulation can further optimize the pro-angiogenic potential of exosomes [138–140]. Exosomes derived from BMSCs pretreated with magnesium ions (Mg-Exos) effectively reversed dexamethasone-induced impairment of angiogenesis in human umbilical vein endothelial cells in vitro, demonstrating synergistic pro-angiogenic and pro-osteogenic effects in the treatment of steroid-induced osteonecrosis of the femoral head [141]. In addition to exosomes derived from BMSCs, Liu et al demonstrated that endothelial cell-derived exosomes can effectively activate the positive feedback loop of osteogenesis–angiogenesis coupling between BMSCs and endothelial cells, thereby promoting bone defect healing in a cascade-amplified manner. These findings provide novel insights into the development of exosome-based biotherapy for bone defect repair [142].
Regulation of the Immune Microenvironment
Precise modulation of the osteoimmune microenvironment is a prerequisite for successful bone regeneration. Although the pro-inflammatory response in the early phase of injury facilitates the clearance of pathogens and necrotic tissues, excessive inflammation inhibits osteogenic differentiation and promotes the formation of fibrotic scars [143]. As key mediators in the osteoimmune axis, exosomes can reprogram the local immune microenvironment from a pro-inflammatory state to a pro-regenerative anti-inflammatory state [144]. Macrophage polarization is a core component of immune regulation [145]. For instance: exosomes derived from M2-polarized macrophages deliver CYLD protein, which dephosphorylates and inactivates STAT3, inhibits osteoclast differentiation to reduce bone resorption, and indirectly optimizes the bone regeneration microenvironment by regulating the immune response [146]; exosomes derived from adipose mesenchymal stem cells prevent osteonecrosis by blocking the NF-κB/NLRP3/IL-1β inflammatory axis, reducing macrophage pyroptosis and the release of pro-inflammatory cytokine s[147]; metabolically glycoengineered exosomes (DS-exo@A2M) significantly inhibit M1 polarization (downregulating TNF-α and IL-6) and promote M2 polarization (upregulating CD206 and Arg-1) by activating the IL-4 signaling pathway, thereby facilitating bone regeneration [148].
Regulation of Osteoclast Activity
Bone homeostasis is maintained by the dynamic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption [149]. Exosomes also play a pivotal role in regulating osteoclastogenesis [150]. Extracellular vesicles derived from osteoclasts carry signaling molecules such as RANK, which can reciprocally regulate osteoblast activity, thereby forming a bidirectional regulatory loop [151]. In pathological bone loss states such as osteoporosis, exosomes reduce bone resorption by inhibiting osteoclast differentiation-related signaling pathways (eg, the OPG axis), thereby maintaining or restoring bone mass [152]. Extracellular vesicles derived from mesenchymal stem cells, osteoblasts, endothelial cells, and macrophages have all been shown to possess the potential to promote bone formation, inhibit bone resorption, and enhance vascularization [153,154].
Exosome-Biomaterial Combinations in Promoting Bone Defect Repair
Combining the pro-osteogenic and regenerative properties of exosomes with biomaterials featuring high strength and anti-tumor activity constitutes an ideal strategy for achieving “elimination of residual lesions + defect repair” following bone tumor surgery. The exosome-functionalized doxorubicin-loaded nanobone cement system developed by Gupta et al exemplifies a typical approach in this field. This system employs degradable nanobone cement as a carrier to co-load the chemotherapeutic agent doxorubicin and functional exosomes, supplemented with an antioxidant herbal film containing Cissus quadrangularis extract to facilitate periosteal regeneration[155]. Metal ions released during the degradation of magnesium- or zinc-containing calcium phosphate bone cement can not only inhibit tumor cell proliferation by inducing reactive oxygen species production and mitochondrial damage but also promote osteogenic differentiation via activation of the BMP/Smad and Wnt/β-catenin signaling pathways [156,157]. Chen et al modified BMSC-derived exosomes with the bone-targeting peptide SDSSD and encapsulated capreomycin within them. This nanoplatform induced ferroptosis in OS cells via the Keap1/Nrf2/GPX4 signaling pathway by triggering excessive reactive oxygen species accumulation, Fe2+ aggregation, and lipid peroxidation, exhibiting significant anti-tumor activity without obvious toxicity in both in vitro and in vivo models. Notably, the osteogenesis-related miRNAs (eg, miR-29a/29c-3p, miR-150-5p) carried by BMSC-derived exosomes themselves endow the platform with the potential to promote bone regeneration [158].
With the advancement of research, investigators have found that titanium alloy (Ti–6Al–4V) is widely used as an implant material for bone defects in weight-bearing regions, owing to its excellent mechanical strength (elastic modulus of approximately 110 GPa, which can be reduced to ~ 3.2 GPa via porous design to match cancellous bone), corrosion resistance, and biocompatibility. However, the surface bioinertness of titanium alloy hinders its effective integration with host bone tissue. Therefore, investigators designed a bionic porous titanium alloy scaffold (BTPS) with an anisotropic and interconnected porous structure using the Voronoi algorithm and imaging data (elastic modulus ≈ 3.2 GPa, permeability 11.52 × 10–8 mm2, pore size 600 μm, porosity 70%), which closely mimics the geometric morphology and mechanical properties of natural cancellous bone. Following modification of the scaffold surface with polydopamine, PEGDA/GelMA double-network hydrogel microspheres encapsulating exosomes derived from hypoxic human umbilical vein endothelial cells were firmly anchored to the scaffold surface; in vitro release experiments confirmed that exosomes could be continuously released for ≥ 30 days. In a rabbit femoral defect model, this composite scaffold significantly increased bone volume, bone mineral density, and neovascular density via activation of the MAPK, mTOR, HIF-1, and VEGF signaling pathways [158].
The 3D-printed exosome-functionalized collagen-coated polycaprolactone (PCL/Col) scaffold also significantly enhanced osteogenic differentiation and bone regeneration in both in vitro and in vivo experiments, embodying the modular design concept of “high-strength scaffold + bioactive coating + exosome functionalization” [159]. Currently, hydrogels serve as ideal carriers for the local delivery of exosomes, owing to their high water content, excellent biocompatibility, and tunable degradation properties. Studies have demonstrated that following co-encapsulation of bone-functionalized BMSC-derived exosomes and ZIF-8 into a GelMA hydrogel composite scaffold (MSC-Exos/ZIF-8@GelMA), ZIF-8 (a zinc-based zeolitic imidazolate framework material) induces macrophage polarization toward the anti-inflammatory M2 phenotype by inhibiting the NF-κB pathway. Anti-inflammatory factors (eg, IL-10, TGF-β) secreted by M2 macrophages further inhibit osteoclast activity and promote the osteogenic differentiation of BMSCs by activating the AKT signaling pathway via miR-23a-3p, thereby forming an “immuno-osteogenic” positive feedback regulatory loop [160]. Driven by the continuous advancements in orthopedics and materials science mentioned above, the concept of 3D bone organoids emerged. These are miniature living tissues that are created in vitro using stem cells, biomaterials, and engineered cultivation techniques; they possess a biomimetic three-dimensional structure, multiple cellular components, and the key functions of bone tissue such as formation, remodeling, and repair[161,162]. In essence, they represent a “miniature bone” capable of simulating bone development and homeostasis within the body. A team from the Center for Growth, Metabolism, and Aging at the School of Life Sciences of Sichuan University, by using SOX9 scl-progenitors under lineage-specific induction, not only generated articular cartilage but also observed spontaneous condensation, formation of chondrolysin, hypertrophy of chondrocytes, and vascular invasion; ultimately, matrix bone formation occurred, thereby reproducing the key stages of endochondral ossification. In addition, self-organized growth plate-like structures have also been induced using SOX9 scl-progenitor-derived fusion constructs with chondro- and osteo-spheroids, exhibiting molecular and cellular similarities to the primary growth plates [163].
Currently, exosomes of plant origin exhibit unique advantages in the fight against bone tumors. The exosomes derived from figs contain PEU-miR-2916-p3, which directly regulates the genes RN7SL1 in mammals (leading to the direct suppression of tumors) and Stab1 (inducing M1 polarization of macrophages), thereby achieving a dual effect of directly killing tumors and reshaping the tumor-suppressing microenvironment [164]. The molecular mechanisms of exosome-mediated bone regeneration and biomaterial integration are summarized and illustrated in Figure 3.
Figure 3. The major molecular mechanism of exosome-mediated bone regeneration and the typical case of combination with biological materials.

MSC-derived exosomes (MSC-Exos) directly promote osteoblast (bone-forming cell) differentiation by inhibiting the PI3K/AKT pathway. MSC-exosomes promote osteogenesis via miR-29a/TET3-mediated BMP2 mRNA demethylation. MSC-exosomes deliver miR-150-5p to upregulate endothelial SOX2, initiating a glycolysis shift for angiogenesis and restoring CD31/Endomucin integrity. Furthermore, Mg-Exo reverses hormone-induced endothelial damage. Engineered DS-exo@A2M promotes M2 polarization via CYLD-mediated STAT3 modulation. Simultaneously, it restrains osteoclastogenesis by blocking the OPG-RANK axis. These actions reduce resorptive bone loss, offering therapeutic potential against tumor- and osteoporosis-induced skeletal destruction. Engineered 3D-printed PEGDA/GelMA scaffolds impregnated with ZIF-8 deliver exosomes. Complemented by doxorubicin/capreomycin/Mg2+-laden bone cement, this synergistic multi-functional depot ensures controlled release, achieving combined anti-tumor, anti-infection, and osteogenic efficacy. PI3K/AKT pathway, Phosphoinositide 3-kinase/Protein Kinase B, a signaling cascade regulating cell proliferation and survival; TET3, Ten-Eleven Translocation 3, a DNA demethylase enzyme; SOX2, SRY-related HMG-box 2; CD31, PECAM-1, a cell adhesion molecule; CYLD, Cylindromatosis, a deubiquitinase; STAT3, Signal Transducer and Activator of Transcription 3, a pivotal signaling node; RANK, Receptor Activator of Nuclear Factor-κB. ↑ indicates an increase in expression. ↓ indicates a decrease in expression. The picture was originally created by us, and the research drawing software of Nano Banana and AI was applied.
Boundary Conditions and Limitations
Accurate interpretation of exosome research in OS requires a clear appreciation of its boundary conditions and evidentiary limitations. A marked gradient exists in the robustness of supporting data: the roles of exosomes in tumor microenvironment remodeling, osteogenesis, and angiogenic coupling are biologically well established, with consistent preclinical validation. Engineered exosomes for drug delivery and exosome–biomaterial composites for bone repair show strong efficacy in small-animal models, but large-animal data remain scarce, precluding late-stage trial progression. Although exosomal miRNAs and proteins exhibit promising diagnostic and prognostic associations in retrospective cohorts, no prospective multi-center study has yet established clinically applicable thresholds, and no exosome-based product for OS has received regulatory approval, with all therapeutic candidates currently at Phase I/II. Beyond this maturity gradient, technical heterogeneity severely compromises reproducibility and cross-study comparability. Divergent isolation and characterization protocols—varying ultracentrifugation parameters, precipitation reagents, and marker panels—produce substantial batch-to-batch variability in purity, yield, and bioactivity, undermining meta-analyses and translational concordance.
Application-specific constraints further limit clinical utility. Diagnostic single-marker approaches are confounded by comorbidities and concurrent treatments, necessitating multi-marker panels that require large-scale validation. Therapeutically, poor in vivo targeting, rapid clearance, and GMP-scale production bottlenecks remain critical hurdles. For regeneration, most preclinical evidence derives from non-tumor defect models, leaving the safety and efficacy of exosome-based interventions in the post-resection OS niche—where residual tumor cells can persist and interact with regenerative cues—largely unexplored.
Therefore, in the aspect of exosomes extraction, we advocate following the “triple standard” recommended by the International Society of Extracellular Vesicles (ISEV) and identifying them from 3 dimensions: morphology (electron microscope), particle size (NTA) and specific marker (western blot). The combination of core markers (CD9, CD63, CD81, Tsg101) should be used in identification, and negative markers (such as Calnexin) must be included to exclude cell debris pollution. When publishing the research, we must follow the mandatory reporting elements of MISEV guidelines [165] and record all experimental parameters in detail. In terms of storage, the storage plan must be made according to “purpose” and “duration”. Long-term storage requires the addition of protective agents. After these problems are standardized, more animal models of bone defect after tumor should be studied, and a large-scale and multi-center cohort covering healthy controls and patients with different disease stages should be established to jointly promote exosomes from laboratory to clinical application.
Future Directions
Translating exosome-based strategies into OS clinical practice requires overcoming critical hurdles. First, the dual tumor-promoting versus regenerative functions demand engineering solutions that spatially and temporally separate anti-tumor and osteogenic activities, particularly in the post-resection niche where residual disease and bone repair coexist. Second, standardized isolation and characterization protocols strictly adhering to MISEV guidelines are essential for reproducibility. Third, large-animal models of tumor-bearing bone defects are urgently needed, as most regenerative data derive from non-tumor defects, leaving safety and efficacy in the true OS microenvironment unexplored. Fourth, engineering advances—bone-targeting ligands, controlled-release biomaterial scaffolds, and exosome-mimetics—should prioritize in vivo delivery efficiency and long-term biocompatibility. Finally, multi-center prospective cohorts are essential to validate exosomal biomarkers for early diagnosis and prognostic monitoring, moving beyond retrospective associations. Interdisciplinary collaboration among oncologists, bioengineers, immunologists, and orthopedic surgeons will be pivotal to translate these versatile nanocarriers from bench to bedside, ultimately achieving integrated tumor eradication and functional skeletal restoration in OS patients.
Conclusions
In summary, exosomes are central mediators of intercellular communication, with dual functions spanning OS pathogenesis, management, and post-resection bone repair. Through cargo–signal delivery, they influence proliferation, invasion, pre-metastatic niche formation, immune evasion, and chemoresistance, while also contributing to osteogenesis, angiogenesis, and immunomodulation. This bifunctional nature suggests exosomes could serve as a unifying platform to address both tumor control and functional restoration. Preclinically, they show potential as non-invasive liquid biopsy biomarkers and as natural nanocarriers for targeted therapy. Exosome-functionalized biomaterial scaffolds may offer an integrated approach combining mechanical support, drug delivery, and regenerative cues, potentially enabling concurrent residual disease eradication and segmental bone defect repair. However, these applications remain largely investigational, and their clinical impact awaits rigorous validation.
Nevertheless, clinical translation remains in its infancy, hindered by the absence of standardized isolation and quality-control protocols, limited targeting efficiency, and unresolved long-term safety. Future efforts should prioritize: (1) international consensus on exosome characterization and quantification, (2) rigorous large-animal and multicentre clinical validation, (3) advanced engineering to improve specificity and efficacy, and (4) mechanistic dissection of their anti-tumor and pro-regenerative actions. With sustained interdisciplinary collaboration across oncology, immunology, materials science, and orthopedics, exosomes hold the potential to bridge treatment and repair, paving the way for safer, more effective, and personalized strategies that improve both survival and quality of life for OS patients.
Footnotes
Financial support: This work was supported by Jilin Provincial Department of Science and Technology (20210101425JC), Jilin Provincial Department of Education (JJKH20210578KJ), and the Jilin Provincial Medical and Health Talent Construction Project (2025WSZX-ZH24)
Conflict of interest: None declared
Publisher’s note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher
Declaration of Figures’ Authenticity: All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.
References
- 1.Robinson MJ, Davis EJ. Neoadjuvant chemotherapy for adults with osteogenic sarcoma. Curr Treat Options Oncol. 2024;25(11):1366–73. doi: 10.1007/s11864-024-01269-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Yadwad AR, Iyer JR, Korikani M, et al. Bone cancer. In: Kancha RK, editor. Biomedical aspects of solid cancers. Singapore: Springer Nature Singapore; 2024. pp. 253–64. [Google Scholar]
- 3.Kim C, Davis LE, Albert CM, et al. Osteosarcoma in pediatric and adult populations: are adults just big kids? Cancers (Basel) 2023;15(20):5044. doi: 10.3390/cancers15205044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Rubio-San-Simón A, Wilson W, Sironi G, et al. Prognostic factors in patients with relapsed high-grade osteosarcoma: A systematic review. Br J Cancer. 2025;133(7):1020–28. doi: 10.1038/s41416-025-03118-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Wang H, Zhu T, Yang K, et al. Decoding the immune microenvironment in osteosarcoma: New insights into checkpoints, vaccines, and CAR-T cells. Front Oncol. 2025;15:1702219. doi: 10.3389/fonc.2025.1702219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Yang B, Liu S, Liu B, et al. A conceptual blueprint for “turning cold to hot” in Osteosarcoma: From TME stratification hypotheses to adaptive therapeutic prospects. Cell Commun Signal. 2026;24(1):298. doi: 10.1186/s12964-026-02883-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Zhang M, Li Y, Feng T, et al. Bone engineering scaffolds with exosomes: A promising strategy for bone defects repair. Front Bioeng Biotechnol. 2022;10:920378. doi: 10.3389/fbioe.2022.920378. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Weidlich A, Schaser K-D, Weitz J, et al. Surgical and oncologic outcome following sacrectomy for primary malignant bone tumors and locally recurrent rectal cancer. Cancers. 2024;16(13):2334. doi: 10.3390/cancers16132334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Alzhrani GN, Alanazi ST, Alsharif SY, et al. Exosomes: Isolation, characterization, and biomedical applications. Cell Biol Int. 2021;45(9):1807–31. doi: 10.1002/cbin.11620. [DOI] [PubMed] [Google Scholar]
- 10.Poe AJ, Knowlton AA. Exosomes as agents of change in the cardiovascular system. J Mol Cell Cardiol. 2017;111:40–50. doi: 10.1016/j.yjmcc.2017.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zhongyu X, Wei X, Hongmei Z, et al. Review of pre-metastatic niches induced by osteosarcoma-derived extracellular vesicles in lung metastasis: A potential opportunity for diagnosis and intervention. Biomed Pharmacother. 2024;178:117203. doi: 10.1016/j.biopha.2024.117203. [DOI] [PubMed] [Google Scholar]
- 12.Lin Z, Wu Y, Xu Y, et al. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: Recent advances and therapeutic potential. Mol Cancer. 2022;21(1):179. doi: 10.1186/s12943-022-01650-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ye H, Tan L, Tu C, Min L. Exosomes in sarcoma: Prospects for clinical applications. Crit Rev Oncol Hematol. 2023;181:103895. doi: 10.1016/j.critrevonc.2022.103895. [DOI] [PubMed] [Google Scholar]
- 14.Pei Y, Guo Y, Wang W, et al. Extracellular vesicles as a new frontier of diagnostic biomarkers in osteosarcoma diseases: A bibliometric and visualized study. Front Oncol. 2024;14:1359807. doi: 10.3389/fonc.2024.1359807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Hu W, Wang W, Chen Z, et al. Engineered exosomes and composite biomaterials for tissue regeneration. Theranostics. 2024;14(5):2099–126. doi: 10.7150/thno.93088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Mao B, Zhang J, An L, Shao X. Extracellular vesicles in osteosarcoma: Bridging resistance, immunity, and clinical translation. J Bone Oncol. 2026;59:100777. doi: 10.1016/j.jbo.2026.100777. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Wang J, Shi K. Role of tumor-derived exosomes and immune cells in osteosarcoma progression and targeted therapy. Front Immunol. 2025;16:1658358. doi: 10.3389/fimmu.2025.1658358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Goto K, Watanabe D, Yanagida K, et al. Harnessing miRNA-containing extracellular vesicles from mesenchymal stromal cell-derived extracellular vesicles for regeneration of bone defects: A narrative review of mechanisms, biomaterials, and clinical translation. Cancers (Basel) 2025;17(15):2438. doi: 10.3390/cancers17152438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722–35. doi: 10.1038/nrc3838. [DOI] [PubMed] [Google Scholar]
- 20.Zou C, Huang R, Lin T, et al. Age-dependent molecular variations in osteosarcoma: Implications for precision oncology across pediatric, adolescent, and adult patients. Front Oncol. 2024;14:1382276. doi: 10.3389/fonc.2024.1382276. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kamal AF, Putra A, Widodo W. Vascularized fibular graft as a surgical option for osteosarcoma of distal humerus: A case report. Int J Surg Case Rep. 2017;39:280–84. doi: 10.1016/j.ijscr.2017.08.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Gümüştaş SA, Çevik HB, Kayahan S. An epidemiological study of primary bone tumors of the fibula. Arch Bone Jt Surg. 2021;9(5):548–53. doi: 10.22038/abjs.2020.47057.2299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Montgomery RM. Osteosarcoma: Integrating epidemiological insights, genomic advances, environmental determinants, and novel therapeutic strategies in contemporary oncological practice. Preprints: Preprints; 2025. [Google Scholar]
- 24.Yue J, Chen ZS, Xu XX, Li S. Functions and therapeutic potentials of exosomes in osteosarcoma. Acta Mater Med. 2022;1(4):552–62. doi: 10.15212/amm-2022-0024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020;6(5):724–34. doi: 10.1001/jamaoncol.2020.0197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–35. doi: 10.1200/JCO.2014.59.4895. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Liu X, Ye J, Guo W, Wang J. Significance of exosomes in osteosarcoma research: A systematic review and meta-analysis of a singular clinical investigation. Front Cell Dev Biol. 2024;12:14730044. doi: 10.3389/fcell.2024.1473044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Biermann JS, Hirbe A, Ahlawat S, et al. Bone cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(4):e250017. doi: 10.6004/jnccn.2025.0017. [DOI] [PubMed] [Google Scholar]
- 29.PosthumaDeBoer J, Würdinger T, Graat HC, et al. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer. 2011;11:156. doi: 10.1186/1471-2407-11-156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Zeng Y, Fu BM. Resistance mechanisms of anti-angiogenic therapy and exosomes-mediated revascularization in cancer. Front Cell Dev Biol. 2020;8:610661. doi: 10.3389/fcell.2020.610661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Wang J, Shi K. Role of tumor-derived exosomes and immune cells in osteosarcoma progression and targeted therapy. Front Immunol. 2025;16:1658358. doi: 10.3389/fimmu.2025.1658358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1–10. doi: 10.1016/j.canlet.2020.12.024. [DOI] [PubMed] [Google Scholar]
- 33.Yu T, Jiang W, Wang Y, et al. Chimeric antigen receptor T cells in the treatment of osteosarcoma (review) Int J Oncol. 2024;64(4):40. doi: 10.3892/ijo.2024.5628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Deng L, Liu Y, Wu Q, et al. Exosomes to exosome-functionalized scaffolds: A novel approach to stimulate bone regeneration. Stem Cell Res Ther. 2024;15(1):407. doi: 10.1186/s13287-024-04024-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Tajafrooz F, Ghofrani S, Sadeghghomi F, et al. Exosome-based therapeutics in bone regeneration: from fundamental biology to clinical translation. Stem Cell Res Ther. 2025;16(1):555. doi: 10.1186/s13287-025-04686-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Hu S, Wang S, Yang X, et al. Exosomes promise better bone regeneration. Regen Ther. 2025;30:389–402. doi: 10.1016/j.reth.2025.06.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Cho S, Jeon DG, Cho WH, et al. Proximal femur salvage in revision knee arthroplasty due to oncologic indications: Long-term results of onlay and overlapping allograft in revision surgeries. Clin Orthop Surg. 2023;15(5):853–63. doi: 10.4055/cios22254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. doi: 10.1126/science.aau6977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wang YY, Cheng J, Liu YD, et al. Exosome-based regenerative rehabilitation: A novel ice breaker for neurological disorders. Biomed Pharmacother. 2023;169:115920. doi: 10.1016/j.biopha.2023.115920. [DOI] [PubMed] [Google Scholar]
- 40.Mahamed R, Monchusi B, Penny C, Mirza S. Cancer-derived exosomes: Mediators of immune crosstalk and emerging targets for immunotherapy. Front Immunol. 2025;16:1679934. doi: 10.3389/fimmu.2025.1679934. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Zhao J, Zhu W, Mao Y, et al. Unignored intracellular journey and biomedical applications of extracellular vesicles. Adv Drug Deliv Rev. 2024;212:115388. doi: 10.1016/j.addr.2024.115388. [DOI] [PubMed] [Google Scholar]
- 42.Ludwig AK, Giebel B. Exosomes: Small vesicles participating in intercellular communication. Int J Biochem Cell Biol. 2012;44(1):11–15. doi: 10.1016/j.biocel.2011.10.005. [DOI] [PubMed] [Google Scholar]
- 43.Nayak A, Nishank SS. Deciphering the contributions of extracellular vesicles to cancer metastasis: Mechanisms and therapeutic implications. Crit Rev Oncol Hematol. 2025;216:104927. doi: 10.1016/j.critrevonc.2025.104927. [DOI] [PubMed] [Google Scholar]
- 44.Tan S, Yang Y, Yang W, et al. Exosomal cargos-mediated metabolic reprogramming in tumor microenvironment. J Exp Clin Cancer Res. 2023;42(1):59. doi: 10.1186/s13046-023-02634-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Krylova SV, Feng D. The machinery of exosomes: Biogenesis, release, and uptake. Int J Mol Sci. 2023;24(2):1337. doi: 10.3390/ijms24021337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Wang Y, Yang Q, Fang D, et al. Progress in exosome-related research supported by the National Natural Science Foundation of China. Fundam Res. 2025;5(5):2318–29. doi: 10.1016/j.fmre.2023.05.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Vietri M, Radulovic M, Stenmark H. The many functions of ESCRTs. Nat Rev Mol Cell Biol. 2020;21(1):25–42. doi: 10.1038/s41580-019-0177-4. [DOI] [PubMed] [Google Scholar]
- 48.Liese S, Wenzel EM, Kjos I, et al. Protein crowding mediates membrane remodeling in upstream ESCRT-induced formation of intraluminal vesicles. Proc Natl Acad Sci USA. 2020;117(46):28614–24. doi: 10.1073/pnas.2014228117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Woodman PG, Futter CE. Multivesicular bodies: Co-ordinated progression to maturity. Curr Opin Cell Biol. 2008;20(4):408–14. doi: 10.1016/j.ceb.2008.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Wenzel EM, Schultz SW, Schink KO, et al. Concerted ESCRT and clathrin recruitment waves define the timing and morphology of intraluminal vesicle formation. Nat Commun. 2018;9(1):2932. doi: 10.1038/s41467-018-05345-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Arya SB, Chen S, Jordan-Javed F, Parent CA. Ceramide-rich microdomains facilitate nuclear envelope budding for non-conventional exosome formation. Nat Cell Biol. 2022;24(7):1019–28. doi: 10.1038/s41556-022-00934-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Kim Y, D’Acunzo P, Levy E. Biogenesis and secretion of mitovesicles, small extracellular vesicles of mitochondrial origin at the crossroads between brain health and disease. Curr Opin Physiol. 2024;40:100765. doi: 10.1016/j.cophys.2024.100765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Picca A, Guerra F, Calvani R, et al. Generation and release of mitochondrial-derived vesicles in health, aging and disease. J Clin Med. 2020;9(5):1440. doi: 10.3390/jcm9051440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Sharma A. Mitochondrial cargo export in exosomes: Possible pathways and implication in disease biology. J Cell Physiol. 2023;238(4):687–97. doi: 10.1002/jcp.30967. [DOI] [PubMed] [Google Scholar]
- 55.Yang J, Liao C, Liang X, et al. CD147 promotes NSCLC metastasis by inducing secretory autophagy-dependent exosome secretion via TRIM56-mediated ubiquitination and degradation of GCN2. Cell Death Differ. 2025;33(6):1152–74. doi: 10.1038/s41418-025-01636-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Van Hoecke L, Vandendriessche C, Hochepied T, et al. Challenging the conventional wisdom: Re-evaluating Smpd3’s role in extracellular vesicle biogenesis. J Extracell Biol. 2024;3(11):e70015. doi: 10.1002/jex2.70015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Prada I, Meldolesi J. Binding and fusion of extracellular vesicles to the plasma membrane of their cell targets. Int J Mol Sci. 2016;17(8):1296. doi: 10.3390/ijms17081296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Xiang H, Bao C, Chen Q, et al. Extracellular vesicles (EVs)’ journey in recipient cells: From recognition to cargo release. J Zhejiang Univ Sci B. 2024;25(8):633–55. doi: 10.1631/jzus.B2300566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Kwantwi LB. Exosome-mediated crosstalk between tumor cells and innate immune cells: Implications for cancer progression and therapeutic strategies. J Cancer Res Clin Oncol. 2023;149(11):9487–503. doi: 10.1007/s00432-023-04833-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Lin XP, Mintern JD, Gleeson PA. Macropinocytosis in different cell types: Similarities and differences. Membranes (Basel) 2020;10(8):177. doi: 10.3390/membranes10080177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Miyanishi M, Tada K, Koike M, et al. Identification of Tim4 as a phosphatidylserine receptor. Nature. 2007;450(7168):435–39. doi: 10.1038/nature06307. [DOI] [PubMed] [Google Scholar]
- 62.Wan Z, Zhao L, Lu F, et al. Mononuclear phagocyte system blockade improves therapeutic exosome delivery to the myocardium. Theranostics. 2020;10(1):218–30. doi: 10.7150/thno.38198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Abdeen A, Sonoda H, Kaito A, et al. Decreased excretion of urinary exosomal Aquaporin-2 in a puromycin aminonucleoside-induced nephrotic syndrome model. Int J Mol Sci. 2020;21(12):4288. doi: 10.3390/ijms21124288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Ju J, Neuen SML, van Zandvoort M, et al. Extracellular vesicles: Cargo loading, degradation and secretory pathways, and their intersection with autophagy. Extracell Vesicles Circ Nucl Acids. 2025;6(3):360–85. doi: 10.20517/evcna.2025.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Li M, Wang Y, Zhang H, et al. The recent progress of tumor cell-derived exosomes in the pathogenesis, diagnosis and therapeutic strategies of tumors. J Transl Med. 2025;23(1):925. doi: 10.1186/s12967-025-06883-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Mohammed O, Ahmed Assaye M, Alemayehu E, et al. Exosomes in cancer metabolism and drug resistance: A review. Biomol Biomed. 2025;26(5):730–45. doi: 10.17305/bb.2025.13295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Khidr WA, Alfarttoosi KH, Taher WM, et al. A review of the role of tumor-derived exosomes in cancers treatment and progression. Int Immunopharmacol. 2025;157:114782. doi: 10.1016/j.intimp.2025.114782. [DOI] [PubMed] [Google Scholar]
- 68.Ramu D, Kim E. Exosomal lipids in cancer progression and metastasis. Cancer Med. 2025;14(6):e70687. doi: 10.1002/cam4.70687. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Xie M, Yu T, Jing X, et al. Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582–3p/HUR/VEGF axis and suppressing HSP90 degradation. Mol Cancer. 2020;19(1):112. doi: 10.1186/s12943-020-01208-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Liu K, Wang Y, Li Q, et al. Hypoxia LUAD H1975 cell-derived exosomal miR-671-3p promotes angiogenesis via regulating KLF2-VEGFR2 axis. Sci Rep. 2025;15(1):13148. doi: 10.1038/s41598-025-97488-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Chen H, Liu L, Xing G, et al. Exosome tropism and various pathways in lung cancer metastasis. Front Immunol. 2025;16:1517495. doi: 10.3389/fimmu.2025.1517495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Zhang X, Sheng Y, Li B, et al. Ovarian cancer derived PKR1 positive exosomes promote angiogenesis by promoting migration and tube formation in vitro. Cell Biochem Funct. 2021;39(2):308–16. doi: 10.1002/cbf.3583. [DOI] [PubMed] [Google Scholar]
- 73.Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120. doi: 10.1038/s41467-020-18794-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Adedokun KA, Bello A, Oyeniyi GM, et al. Exosomal nanocarriers of immune fate: Molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies. Clin Exp Immunol. 2026;220(1):uxag009. doi: 10.1093/cei/uxag009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Liang K, Sun Y, Xie L, et al. Biologically self-assembled tumor cell-derived cancer nanovaccines as an all-in-one platform for cancer immunotherapy. ACS Nano. 2024;18(8):6702–17. doi: 10.1021/acsnano.4c01050. [DOI] [PubMed] [Google Scholar]
- 76.Baena JC, Cabrera-Salcedo SC, Carrera Suárez Y, et al. The avatar principle: Exosomal dynamics guiding tumor adaptation and next-generation therapeutic strategies. J Nanobiotechnology. 2026;24(1):159. doi: 10.1186/s12951-026-04089-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Nikfarjam S, Rezaie J, Kashanchi F, Jafari R. Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res. 2020;39(1):258. doi: 10.1186/s13046-020-01781-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Wadhonkar K, Das S, Subramanian R, et al. The effect of cancer cell-derived exosomal proteins on macrophage polarization: An in-depth review. Exp Cell Res. 2025;444(2):114393. doi: 10.1016/j.yexcr.2024.114393. [DOI] [PubMed] [Google Scholar]
- 79.Clayton A, Mitchell JP, Court J, et al. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008;180(11):7249–58. doi: 10.4049/jimmunol.180.11.7249. [DOI] [PubMed] [Google Scholar]
- 80.Liu QW, Chen Y, Li JY, et al. Bone marrow cells are differentiated into MDSCs by BCC-Ex through down-regulating the expression of CXCR4 and activating STAT3 signalling pathway. J Cell Mol Med. 2021;25(12):5497–510. doi: 10.1111/jcmm.16559. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–86. doi: 10.1038/s41586-018-0392-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Wang X, Zhang H, Yang H, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020;14(3):539–55. doi: 10.1002/1878-0261.12629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Zhang X, Li J, Huang Y, et al. Plasma extracellular vesicles from recurrent GBMs carrying LDHA to activate glioblastoma stemness by enhancing glycolysis. Theranostics. 2025;15(8):3655–72. doi: 10.7150/thno.102014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Dong L, Zheng S, Feng Y. Hypoxia-induced immunosuppression in uveal melanoma is mediated by CD63(+) exosomes delivering lactate to reprogram immune cells. Front Mol Biosci. 2025;12:1743009. doi: 10.3389/fmolb.2025.1743009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Wang W, Yang Q, Li J, et al. Exosomes and metabolic reprogramming crosstalk in breast cancer ecosystem: New insights and therapeutic prospects. Sci Bull (Beijing) 2026;71(1):23–27. doi: 10.1016/j.scib.2025.05.029. [DOI] [PubMed] [Google Scholar]
- 86.Yang P, Qin H, Li Y, et al. CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis. Nat Commun. 2022;13(1):5782. doi: 10.1038/s41467-022-33349-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Xu S, Peng X, Wang Z, et al. FABP7-mediated lipid-laden macrophages drive the formation of pre-metastatic niche and liver metastasis. Int J Biol Sci. 2025;21(10):4388–409. doi: 10.7150/ijbs.110750. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Jiang Y, Zhao Z, Ma L, et al. Exosomal circUBR5 drives metastasis and chemoresistance in gastric signet-ring cell carcinoma by reprogramming cholesterol metabolism through the hsa-miR-1208/CYP19A1 axis and ACAT1 upregulation. Cancer Lett. 2026;641:218279. doi: 10.1016/j.canlet.2026.218279. [DOI] [PubMed] [Google Scholar]
- 89.Yan W, Wu X, Zhou W, et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol. 2018;20(5):597–609. doi: 10.1038/s41556-018-0083-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Yamamoto T, Nakayama J, Urabe F, et al. Aberrant regulation of serine metabolism drives extracellular vesicle release and cancer progression. Cell Rep. 2024;43(8):114517. doi: 10.1016/j.celrep.2024.114517. [DOI] [PubMed] [Google Scholar]
- 91.Sansone P, Savini C, Kurelac I, et al. Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci USA. 2017;114(43):E9066–e75. doi: 10.1073/pnas.1704862114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Birru B, Durthi CP, Kacham S, et al. Stem cells in tumour microenvironment aid in prolonged survival rate of cancer cells and developed drug resistance: Major challenge in osteosarcoma treatment. Curr Drug Metab. 2020;21(1):44–52. doi: 10.2174/1389200221666200214120226. [DOI] [PubMed] [Google Scholar]
- 93.Chang X, Tan Q, Xu J, et al. Tumor-derived exosomal linc00881 induces lung fibroblast activation and promotes osteosarcoma lung migration. Cancer Cell Int. 2023;23(1):287. doi: 10.1186/s12935-023-03121-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Qi J, Zhang R, Wang Y. Exosomal miR-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1. J Cell Mol Med. 2021;25(23):11016–30. doi: 10.1111/jcmm.17024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Shimbo K, Miyaki S, Ishitobi H, et al. Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem Biophys Res Commun. 2014;445(2):381–87. doi: 10.1016/j.bbrc.2014.02.007. [DOI] [PubMed] [Google Scholar]
- 96.Luongo M, Laurenziello P, Cesta G, et al. The molecular conversations of sarcomas: Exosomal non-coding RNAs in tumor’s biology and their translational prospects. Mol Cancer. 2024;23(1):172. doi: 10.1186/s12943-024-02083-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Ji Z, Shen J, Lan Y, et al. Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. MedComm (2020) 2023;4(4):e308. doi: 10.1002/mco2.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Otoukesh B, Abbasi M, Gorgani HO, et al. MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma. Cancer Cell Int. 2020;20:254. doi: 10.1186/s12935-020-01342-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Troyer RM, Ruby CE, Goodall CP, et al. Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. Exp Cell Res. 2017;358(2):369–76. doi: 10.1016/j.yexcr.2017.07.011. [DOI] [PubMed] [Google Scholar]
- 100.Tang J, He J, Feng C, Tu C. Exosomal MiRNAs in osteosarcoma: Biogenesis and biological functions. Front Pharmacol. 2022;13:902049. doi: 10.3389/fphar.2022.902049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Wang S, Ma F, Feng Y, et al. Role of exosomal miR-21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (review) Int J Oncol. 2020;56(5):1055–63. doi: 10.3892/ijo.2020.4992. [DOI] [PubMed] [Google Scholar]
- 102.Niu X, Zhang X, Li Z, Tian W. Multi-transcriptomics analysis of ferroptosis related genes reveals CAFs exosomal COX4I2 as a novel therapeutic target in osteosarcoma. Front Cell Dev Biol. 2025;13:1620648. doi: 10.3389/fcell.2025.1620648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Xu JF, Wang YP, Zhang SJ, et al. Exosomes containing differential expression of microRNA and mRNA in osteosarcoma that can predict response to chemotherapy. Oncotarget. 2017;8(44):75968–78. doi: 10.18632/oncotarget.18373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Wang J, Zhang H, Sun X, et al. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients. J Nanobiotechnology. 2020;18(1):151. doi: 10.1186/s12951-020-00710-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Hu J, Gao D. Recent advances in aptamer-based microfluidic biosensors for the isolation, signal amplification and detection of exosomes. Sensors (Basel) 2025;25(3):848. doi: 10.3390/s25030848. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Liu YJ, Kyne M, Kang C, Wang C. Raman spectroscopy in extracellular vesicles analysis: Techniques, applications and advancements. Biosens Bioelectron. 2025;270:116970. doi: 10.1016/j.bios.2024.116970. [DOI] [PubMed] [Google Scholar]
- 107.Li Y, Yin P, Guo Z, et al. Bone-derived extracellular vesicles: novel players of interorgan crosstalk. Front Endocrinol (Lausanne) 2019;10:846. doi: 10.3389/fendo.2019.00846. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Li Y, Yin P, Guo Z, et al. Bone-derived extracellular vesicles: novel players of interorgan crosstalk. Front Endocrinol (Lausanne) 2019;10:846. doi: 10.3389/fendo.2019.00846. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Zhai C, Xu J, Yang Y, et al. Heterogeneous analysis of extracellular vesicles for osteosarcoma diagnosis. Anal Chem. 2024;96(23):9486–92. doi: 10.1021/acs.analchem.4c00941. [DOI] [PubMed] [Google Scholar]
- 110.Kok VC, Yu CC. Cancer-derived exosomes: Their role in cancer biology and biomarker development. Int J Nanomedicine. 2020;15:8019–36. doi: 10.2147/IJN.S272378. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Wu Y, Ma R, Jiang H. Engineered exosome biomedical technologies for precision diagnosis and therapy in orthopedic diseases. Front Med (Lausanne) 2026;13:1788658. doi: 10.3389/fmed.2026.1788658. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Moharana AK, Panner Selvam MK, Jena SR, et al. Comparative proteomics of seminal exosomes reveals size-exclusion chromatography outperforms ultracentrifugation. Biomedicines. 2025;13(10):2459. doi: 10.3390/biomedicines13102459. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Kurian TK, Banik S, Gopal D, et al. Elucidating methods for isolation and quantification of exosomes: A review. Mol Biotechnol. 2021;63(4):249–66. doi: 10.1007/s12033-021-00300-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.López-Guerrero JA, Valés-Gómez M, Borrás FE, et al. Standardising the preanalytical reporting of biospecimens to improve reproducibility in extracellular vesicle research – A GEIVEX study. J Extracell Biol. 2023;2(4):e76. doi: 10.1002/jex2.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Li J, Xia Y, Peng J, Chen Z. Exosome-based liquid biopsy: A new frontier in early cancer diagnosis. Biosci Trends. 2025;19(5):589–93. doi: 10.5582/bst.2025.01142. [DOI] [PubMed] [Google Scholar]
- 116.Logozzi M, Mizzoni D, Di Raimo R, et al. Plasmatic exosome number and size distinguish prostate cancer patients from healthy individuals: A prospective clinical study. Front Oncol. 2021;11:727317. doi: 10.3389/fonc.2021.727317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.Yang L, Huang X, Guo H, et al. Exosomes as efficient nanocarriers in osteosarcoma: Biological functions and potential clinical applications. Front Cell Dev Biol. 2021;9:737314. doi: 10.3389/fcell.2021.737314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118.Yao P, Lu Y, Cai Z, et al. Research progress of exosome-loaded miRNA in osteosarcoma. Cancer Control. 2022;29:10732748221076683. doi: 10.1177/10732748221076683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Tian W, Niu X, Feng F, et al. The promising roles of exosomal microRNAs in osteosarcoma: A new insight into the clinical therapy. Biomed Pharmacother. 2023;163:114771. doi: 10.1016/j.biopha.2023.114771. [DOI] [PubMed] [Google Scholar]
- 120.Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. 2020;21(16):5840. doi: 10.3390/ijms21165840. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Leng Y, Li J, Long Z, et al. Osteoblast-derived exosomes promote osteogenic differentiation of osteosarcoma cells via URG4/Wnt signaling pathway. Bone. 2024;178:116933. doi: 10.1016/j.bone.2023.116933. [DOI] [PubMed] [Google Scholar]
- 122.Liu X, Ye J, Guo W, Wang J. Significance of exosomes in osteosarcoma research: A systematic review and meta-analysis of a singular clinical investigation. Front Cell Dev Biol. 2024;12:1473044. doi: 10.3389/fcell.2024.1473044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Al-Hawary SIS, Almajidi YQ, Bansal P, et al. Dendritic cell-derived exosome (DEX) therapy for digestive system cancers: Recent advances and future prospect. Pathol Res Pract. 2024;257:155288. doi: 10.1016/j.prp.2024.155288. [DOI] [PubMed] [Google Scholar]
- 124.Huang D, Huang W, Liu M, et al. Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs. Cancer Cell Int. 2025;25(1):169. doi: 10.1186/s12935-025-03795-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Shi Y, Zhang J, Li Y, et al. Engineered mesenchymal stem/stromal cells against cancer. Cell Death Dis. 2025;16(1):113. doi: 10.1038/s41419-025-07443-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Cordelier P. Unveiling the nexus: Oncolytic viruses, extracellular vesicles, and immune modulation. Mol Ther Oncol. 2025;33(1):200940. doi: 10.1016/j.omton.2025.200940. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Safarzadeh M, Saadat N, Abbasi-Molaei S, Rastegari-Pouyani M. Extracellular vesicles as missiles for enhanced anti-tumor efficacy of oncolytic viruses: From disseminating oncolysis and anti-tumor immunity to targeted delivery. Cell Commun Signal. 2025;23(1):276. doi: 10.1186/s12964-025-02283-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.Wei H, Chen F, Chen J, et al. Mesenchymal stem cell derived exosomes as nanodrug carrier of doxorubicin for targeted osteosarcoma therapy via SDF1-CXCR4 Axis. Int J Nanomedicine. 2022;17:3483–95. doi: 10.2147/IJN.S372851. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Yamaguchi DT. “Ins” and “Outs” of mesenchymal stem cell osteogenesis in regenerative medicine. World J Stem Cells”. 2014;6(2):94–110. doi: 10.4252/wjsc.v6.i2.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Qin Y, Sun R, Wu C, et al. Exosome: A novel approach to stimulate bone regeneration through regulation of osteogenesis and angiogenesis. Int J Mol Sci. 2016;17(5):712. doi: 10.3390/ijms17050712. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Chen X, Xie W, Zhang M, et al. The emerging role of non-coding RNAs in osteogenic differentiation of human bone marrow mesenchymal stem cells. Front Cell Dev Biol. 2022;10:903278. doi: 10.3389/fcell.2022.903278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Lin Q, Sun W, Zhao B, et al. Delivery of miR-29a/29c-3p by serum exosomes promotes osteogenesis through TET3-dependent Sox9 demethylation and PI3K/Akt activation. J Nanobiotechnology. 2025;23(1):751. doi: 10.1186/s12951-025-03743-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Liao X, Yang Z, Li Y, et al. M2 macrophage-derived exosome facilitates aerobic glycolysis and osteogenic differentiation of hPDLSCs by regulating TRIM26-induced PKM ubiquitination. Free Radic Biol Med. 2025;237:88–100. doi: 10.1016/j.freeradbiomed.2025.05.425. [DOI] [PubMed] [Google Scholar]
- 134.Yang Z, Dong Y, Dong Z, et al. Targeted delivery of exosomal Bmp2 mRNA via a bioadhesive interface synergistically enhances titanium implant osseointegration. Small. 2025;21(51):e10386. doi: 10.1002/smll.202510386. [DOI] [PubMed] [Google Scholar]
- 135.Fu S, Liu L, Xu F, et al. Small extracellular vesicles produced by homeostatic phenotype BMSC promote bone regeneration by transferring anti-senescent factor JMJD6. J Nanobiotechnology. 2026;24(1):286. doi: 10.1186/s12951-026-04199-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136.Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 2014;507(7492):323–28. doi: 10.1038/nature13145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 137.Wu F, Song C, Zhen G, et al. Exosomes derived from BMSCs in osteogenic differentiation promote type H blood vessel angiogenesis through miR-150-5p mediated metabolic reprogramming of endothelial cells. Cell Mol Life Sci. 2024;81(1):344. doi: 10.1007/s00018-024-05371-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Miceli V. Priming strategies to enhance the therapeutic efficacy of mesenchymal stromal/stem cell-derived vesicles in regenerative medicine. Extracell Vesicles Circ Nucl Acids. 2026;7(1):20–33. doi: 10.20517/evcna.2025.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 139.Alcayaga-Miranda F, Varas-Godoy M, Khoury M. Harnessing the angiogenic potential of stem cell-derived exosomes for vascular regeneration. Stem Cells Int. 2016;2016:3409169. doi: 10.1155/2016/3409169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 140.Todorova D, Simoncini S, Lacroix R, et al. Extracellular vesicles in angiogenesis. Circ Res. 2017;120(10):1658–73. doi: 10.1161/CIRCRESAHA.117.309681. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141.Li L, Cheng L, Du Y, et al. Exosomes derived from Mg-preconditioned bone mesenchymal stem cells promote angiogenesis and osteogenesis for osteonecrosis treatment. Materials (Basel) 2025;18(20):4687. doi: 10.3390/ma18204687. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142.Liu L, Zhou N, Fu S, et al. Endothelial cell-derived exosomes trigger a positive feedback loop in osteogenesis-angiogenesis coupling via up-regulating zinc finger and BTB domain containing 16 in bone marrow mesenchymal stem cell. J Nanobiotechnology. 2024;22(1):721. doi: 10.1186/s12951-024-03002-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Wang H, Chen R, Li X, et al. Exosomes as precise regulators of the osteoimmune microenvironment: Engineering strategies for bone regeneration. Biomater Res. 2026;30:0321. doi: 10.34133/bmr.0321. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 144.Yang L, Li N, Xu H, et al. Immunocyte-derived extracellular vesicles in osteoimmunology: Mechanisms, disease contexts, and translational prospects. Front Immunol. 2025;16:1709048. doi: 10.3389/fimmu.2025.1709048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.Xing J, Li H, Xia H, et al. Macrophages in osteoporotic fractures: From immunometabolic mechanisms to precision therapeutic approaches. Front Endocrinol (Lausanne) 2025;16:1698647. doi: 10.3389/fendo.2025.1698647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 146.Guo ZY, Yin NN, Li XF, et al. Exosomes secreted from M2-polarized macrophages inhibit osteoclast differentiation via CYLD. Tissue Cell. 2025;93:102645. doi: 10.1016/j.tice.2024.102645. [DOI] [PubMed] [Google Scholar]
- 147.Zheng Y, Wang X, He Y, et al. Exosomes from adipose-derived mesenchymal stromal cells prevent medication-related osteonecrosis of the jaw by inhibiting macrophage M1 polarization and pyroptosis. Int J Nanomedicine. 2024;19:12675–93. doi: 10.2147/IJN.S482849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 148.Chen P, Wang R, Fang S. Metabolic glycoengineered exosome-A2M nanoplatform reprograms macrophage polarization and orchestrates bone regeneration in ONFH. Cell Death Discov. 2025;11(1):510. doi: 10.1038/s41420-025-02690-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149.Al-Bari AA, Al Mamun A. Current advances in regulation of bone homeostasis. FASEB Bioadv. 2020;2(11):668–79. doi: 10.1096/fba.2020-00058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 150.Gao M, Gao W, Papadimitriou JM, et al. Exosomes-the enigmatic regulators of bone homeostasis. Bone Res. 2018;6:36. doi: 10.1038/s41413-018-0039-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151.Greenblatt MB, Park KH, Oh H, et al. CHMP5 controls bone turnover rates by dampening NF-κB activity in osteoclasts. J Exp Med. 2015;212(8):1283–301. doi: 10.1084/jem.20150407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 152.Holliday LS, Patel SS, Rody WJ., Jr RANKL and RANK in extracellular vesicles: Surprising new players in bone remodeling. Extracell Vesicles Circ Nucl Acids. 2021;2(1):18–28. doi: 10.20517/evcna.2020.02. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Torrecillas-Baena B, Pulido-Escribano V, Dorado G, et al. Clinical potential of mesenchymal stem cell-derived exosomes in bone regeneration. J Clin Med. 2023;12(13):4385. doi: 10.3390/jcm12134385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 154.Sun J, Yao C, Luo W, et al. Endothelial cell-derived exosomes inhibit osteoblast apoptosis and steroid-induced necrosis of femoral head progression by activating the PI3K/Akt/Bcl-2 pathway. J Tissue Eng Regen Med. 2024;2024:3870988. doi: 10.1155/2024/3870988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 155.Gupta S, Qayoom I, Gupta P, et al. Exosome-functionalized, drug-laden bone substitute along with an antioxidant herbal membrane for bone and periosteum regeneration in bone sarcoma. ACS Appl Mater Interfaces. 2023;15(7):8824–39. doi: 10.1021/acsami.2c18308. [DOI] [PubMed] [Google Scholar]
- 156.Xiong K, Zhang J, Zhu Y, et al. Zinc doping induced differences in the surface composition, surface morphology and osteogenesis performance of the calcium phosphate cement hydration products. Mater Sci Eng C Mater Biol Appl. 2019;105:110065. doi: 10.1016/j.msec.2019.110065. [DOI] [PubMed] [Google Scholar]
- 157.Yu L, Chen J, Shi D, et al. Magnesium phosphate cement modulates osteosarcoma stemness and osteogenesis via IGFBP5 activation for localized tumor therapy. Materials & Design. 2026;263:115643. [Google Scholar]
- 158.Chen W, Li Z, Yu N, et al. Bone-targeting exosome nanoparticles activate Keap1/Nrf2/GPX4 signaling pathway to induce ferroptosis in osteosarcoma cells. J Nanobiotechnology. 2023;21(1):355. doi: 10.1186/s12951-023-02129-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 159.Shemshadsara FG, Ai J, Bayat M, et al. Exosome-functionalized collagen-coated 3D-printed PCL scaffold for enhanced osteogenic differentiation and bone regeneration: An in vitro and in vivo study. J Biol Eng. 2025;19(1):107. doi: 10.1186/s13036-025-00578-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 160.Si Y, Li X, Dong S, et al. Hydrogel scaffold encapsulating MSC-Exos and ZIF-8 promotes bone regeneration via coordinating osteogenesis and immunomodulation. Bioact Mater. 2025;54:329–51. doi: 10.1016/j.bioactmat.2025.08.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 161.Zhu M, Fan Z, Chen M, et al. Biomineralization empowers bone organoids. Biomaterials. 2026;326:123703. doi: 10.1016/j.biomaterials.2025.123703. [DOI] [PubMed] [Google Scholar]
- 162.Huang S, Wu Y, Zhao H, et al. Advancements in bone organoids: Perspectives on construction methodologies and application strategies. J Adv Res. 2026;81:745–67. doi: 10.1016/j.jare.2025.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 163.Xiong J, Ma R, Xie K, et al. Recapitulation of endochondral ossification by hPSC-derived SOX9+ sclerotomal progenitors. Nat Commun. 2025;16(1):2781. doi: 10.1038/s41467-025-58122-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 164.Wang D-d, Qian J, Zou H-z, et al. Fig-derived exosome-like nanoparticles attenuating bone metastasis of breast cancer through establishing an anti-tumor microenvironment. Pharmacol Res. 2026;224:108088. doi: 10.1016/j.phrs.2026.108088. [DOI] [PubMed] [Google Scholar]
- 165.Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. doi: 10.1002/jev2.12404. [DOI] [PMC free article] [PubMed] [Google Scholar]
